AU2016279050A1 - Tumor immunotherapy - Google Patents

Tumor immunotherapy Download PDF

Info

Publication number
AU2016279050A1
AU2016279050A1 AU2016279050A AU2016279050A AU2016279050A1 AU 2016279050 A1 AU2016279050 A1 AU 2016279050A1 AU 2016279050 A AU2016279050 A AU 2016279050A AU 2016279050 A AU2016279050 A AU 2016279050A AU 2016279050 A1 AU2016279050 A1 AU 2016279050A1
Authority
AU
Australia
Prior art keywords
mirna
cells
ste
pct
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016279050A
Other languages
English (en)
Other versions
AU2016279050A2 (en
Inventor
Timothy Kuan-Ta Lu
Lior Nissim
Ming-Ru Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of AU2016279050A1 publication Critical patent/AU2016279050A1/en
Publication of AU2016279050A2 publication Critical patent/AU2016279050A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
AU2016279050A 2015-06-19 2016-06-17 Tumor immunotherapy Abandoned AU2016279050A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562181906P 2015-06-19 2015-06-19
US62/181,906 2015-06-19
US201662325314P 2016-04-20 2016-04-20
US62/325,314 2016-04-20
PCT/US2016/038222 WO2016205737A2 (en) 2015-06-19 2016-06-17 Tumor immunotherapy

Publications (2)

Publication Number Publication Date
AU2016279050A1 true AU2016279050A1 (en) 2018-01-04
AU2016279050A2 AU2016279050A2 (en) 2018-01-04

Family

ID=57546436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016279050A Abandoned AU2016279050A1 (en) 2015-06-19 2016-06-17 Tumor immunotherapy

Country Status (7)

Country Link
US (1) US20190002912A1 (enExample)
EP (1) EP3310915A4 (enExample)
JP (1) JP2018520669A (enExample)
CN (1) CN108350445A (enExample)
AU (1) AU2016279050A1 (enExample)
HK (1) HK1257177A1 (enExample)
WO (1) WO2016205737A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926384T3 (es) 2015-02-06 2022-10-25 Nat Univ Singapore Métodos para mejorar la eficacia de células inmunitarias terapéuticas
CA3031670A1 (en) 2016-07-26 2018-02-01 Senti Biosciences, Inc. Spatiotemporal regulators
WO2018169901A1 (en) * 2017-03-13 2018-09-20 Massachusetts Institute Of Technology Synthetic promoters
KR20200035304A (ko) 2017-08-10 2020-04-02 싱가포르국립대학교 T 세포 수용체-결핍 키메라 항원 수용체 t-세포 및 이의 사용 방법
EP3844289A4 (en) * 2018-08-29 2022-07-20 Shanghaitech University COMPOSITION AND USE OF CAS PROTEIN INHIBITORS
EP3921851B1 (en) * 2019-02-06 2023-10-18 Cornell University Darc expression as prognosticator of immunotherapy outcomes
KR20220137882A (ko) * 2019-12-05 2022-10-12 바이셀릭스, 인크. 보편적 세포 요법을 위한 면역 회피 기작의 조절제
CN116859048A (zh) * 2022-12-09 2023-10-10 上海交通大学医学院附属第九人民医院 肿瘤标志物跨膜蛋白slc31a1及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
WO2008134593A1 (en) * 2007-04-25 2008-11-06 President And Fellows Of Harvard College Molecular circuits
JP2013533847A (ja) * 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ コレステロール関連障害のａａｖベースの治療

Also Published As

Publication number Publication date
US20190002912A1 (en) 2019-01-03
CN108350445A (zh) 2018-07-31
HK1257177A1 (zh) 2019-10-18
EP3310915A2 (en) 2018-04-25
JP2018520669A (ja) 2018-08-02
WO2016205737A3 (en) 2017-02-02
EP3310915A4 (en) 2019-04-10
WO2016205737A2 (en) 2016-12-22
AU2016279050A2 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
AU2016279050A1 (en) Tumor immunotherapy
JP7710644B2 (ja) 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
ES2875959T3 (es) Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
CN113661180B (zh) Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
JP2020195393A (ja) 養子細胞療法用の操作された細胞
JP2021176321A (ja) 養子細胞療法用の操作された細胞
US20210079057A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
US20210128617A1 (en) SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
KR20190053180A (ko) 시공간적 조절자들
KR20230035583A (ko) 키메라 항원 수용체 및 이의 용도
WO2019119822A1 (en) Pharmaceutical chimeric receptor composition and method thereof
US11766453B2 (en) Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs)
Lazarova et al. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system
CN106467576B (zh) 一种抗体融合蛋白及其制备方法与应用
Vachani et al. Gene therapy for lung neoplasms
US20240374641A1 (en) Generation of car modifiers for tumor treatment
CN111629737A (zh) T细胞信号传导的miRNA调节及其应用
Chen Outsmarting and Outmuscling Cancer Cells for Next-Generation CAR-T Cell Therapies
CN120818494A (zh) 一种基于分泌增强策略的car-t细胞及制备方法和医用用途
WO2024245291A1 (zh) 一种金属蛋白酶激活型car-t结构的制备及其应用
WO2023086379A2 (en) Compositions and methods for tcr reprogramming using fusion proteins
HK40010509A (en) Engineered t cells for the treatment of cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 DEC 2017

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application